Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 49

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 49
---
 forma net tangible book value per share. See “ Proposed Business — Permitted Purchases of Our Securities .”

36

SUMMARY FINANCIAL DATA The following table summarizes the relevant financial data for our business and should be read with our financial statements, which are included in this prospectus. We have not had any significant operations to date, and accordingly only balance sheet data is presented.

|                                                            |     | September 30, 2024 |          |             |     |   |             |   |
|:-----------------------------------------------------------|:----|:-------------------|---------:|:------------|:----|:--|------------:|:--|
| Actual                                                     |     |                    |          | As Adjusted |     |   |             |   |
| Working capital (deficiency)(1)                            |     | $                  | (588,903 | )           |     | $ |     516,841 |   |
| Total assets(2)                                            |     | $                  |  426,139 |             |     | $ | 201,935,141 |   |
| Total liabilities(3)                                       |     | $                  |  590,998 |             |     | $ |   6,418,300 |   |
| Value of ordinary shares subject to possible redemption(4) |     | $                  |        — |             |     | $ | 201,000,000 |   |
| Shareholders’ deficit(5)                                   |     | $                  | (164,859 | )           |     | $ |  (5,483,159 | ) |

____________ (1)The “as adjusted” calculation includes $1,100,000 of cash held outside the trust account, including $300,000 to be used to pay for director and officer liability insurance premiums, less $418,300 of over -allotmentliability, less $164,859 of actual shareholders’ deficit on September 30, 2024. (2)The “as adjusted” calculation equals $201,000,000 of cash held in trust from the proceeds of this offering and the sale of the private units, plus $1,100,000 in cash held outside the trust account, including $300,000 to be used to pay for director and officer liability insurance premiums, less $164,859 of actual shareholders’ deficit on September 30, 2024. (3)The “as adjusted” calculation equals $6,000,000 of